Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug179 | Ad5FGF-4 Wiki | 0.71 |
| drug3386 | Tele-medicine platform Wiki | 0.71 |
| drug17 | 14C-lazertinib Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000787 | Angina Pectoris NIH | 1.00 |
| D060050 | Angina, Stable NIH | 0.71 |
| D003324 | Coronary Artery Disease NIH | 0.53 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D054143 | Heart Failure, Systolic NIH | 0.50 |
| D009203 | Myocardial Ischemia NIH | 0.34 |
| D054058 | Acute Coronary Syndrome NIH | 0.32 |
| D007511 | Ischemia NIH | 0.29 |
| D003327 | Coronary Disease NIH | 0.27 |
| D006333 | Heart Failure NIH | 0.22 |
| D002318 | Cardiovascular Diseases NIH | 0.13 |
| D013577 | Syndrome NIH | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.58 |
| HP:0001658 | Myocardial infarction HPO | 0.38 |
| HP:0001635 | Congestive heart failure HPO | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.13 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited exercise duration, angina functional class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life. Half of the study participants will receive Ad5FGF-4, and half will receive placebo. The primary endpoint is the change from baseline to Month 6 in Exercise Tolerance Test (ETT) duration. Long-term safety of Ad5FGF-4 will also be assessed.
Description: Modified Bruce Protocol with exercise duration limited by angina or angina equivalent
Measure: Change in Exercise Tolerance Test (ETT) duration Time: Baseline and Month 6Description: Canadian Cardiovascular Society (CCS) angina classification
Measure: Change in patient functional status (CCS class) Time: Baseline and Month 6Description: Average weekly angina episodes
Measure: Change in weekly angina frequency Time: Baseline and Month 6Description: Average weekly nitroglycerin usage
Measure: Change in weekly nitroglycerin usage Time: Baseline and Month 6Description: Seattle Angina Questionnaire
Measure: Change in quality of life Time: Baseline and Month 6Description: Adverse events and clinical laboratory testing
Measure: Safety of Ad5FGF-4 Time: Through Month 6Description: Occurrence of clinically significant events
Measure: Long-term safety of Ad5FGF-4 Time: Through Month 60Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.
Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context
Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients Time: 6 monthsDescription: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);
Measure: Number of patients included in this platform Time: 6 monthsDescription: Will be the number of sessions per patient multiplied with the number of patients included
Measure: Number of consultations/sessions given Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports